A5008590899- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Fibroblast Growth Factor Research
- Ovarian cancer diagnosis and treatment
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Gallbladder and Bile Duct Disorders
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Estrogen and related hormone effects
- Intraperitoneal and Appendiceal Malignancies
- Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- BRCA gene mutations in cancer
St George Hospital
2016-2025
The University of Sydney
2016-2025
National Health and Medical Research Council
2016-2025
Australia New Zealand Gynaecological Oncology Group
2011-2018
Sutherland Hospital
2016-2018
Cooperative Trials Group for Neuro-Oncology
2017-2018
St. George Hospital
2014-2016
Royal North Shore Hospital
2016
Camden and Campbelltown Hospitals
2015
Bankstown Lidcombe Hospital
2015
Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices International Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets patients with aberrations their tumor that could be targeted currently available therapies.
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for trials. We constructed prognostic nomograms one-year overall survival six-month progression-free in metastatic colorectal carcinoma by using ARCAD database. Data from 22 674 patients 26 randomized phase III trials since 1997 were used to construct validate Cox models, stratified treatment arm within each study. Candidate variables included baseline age, sex, body...
LBA294 Background: AGOC has limited options after second-line therapy. Regorafenib (Rego), an oral multi-targeted tyrosine kinase inhibitor (TKI) targeting angiogenic, stromal and oncogenic receptor TKs, prolonged progression free survival (PFS) versus placebo (PBO) across all regions/subgroups in the INTEGRATE phase 2 randomised trial (JCO 2016 43(23):2728-2735). IIa was designed to examine if Rego improves overall (OS). Methods: Double-blind placebo-controlled 3 comparing + best supportive...
Abstract Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, oncogenic receptor kinases. 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). 80 in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO)....
Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess utilization survival outcomes R/M HNSCC in the real-world setting. A multi-site retrospective chart review was conducted Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), Latin/North America (Brazil Canada) identify who initiated first-line systemic therapy between...
Abstract The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan‐cancer trial platforms that aim to identify signals of clinical activity molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced metastatic cancer patients with tumors harboring cyclin D‐CDK4/6 pathway alterations treated CDK4/6 inhibitors palbociclib...
728 Background: Gemcitabine (GEM) plus nab-paclitaxel (NAB-PAC) is a standard first-line chemotherapy regimen for advanced/metastatic pancreatic ductal adenocarcinoma (PDAC), with median Progression Free Survival (mPFS) and Overall (mOS) of 5.5 & 8.7 in the MPACT trial 5.6 9.2 months (mo) NAPOLI 3 trial, respectively. Certepetide (formerly LSTA1 or CEND-1) novel cyclic peptide that improves targeted penetration co-administered drugs into tumor stroma, leading to potentially increased...
499 Background: Estimating survival in advanced gastric and oesophageal carcinoma (AGOC) remains a significant challenge. We developed prognostic model incorporating readily accessible patient clinical data specific patient-reported outcomes (PROs), utilizing individual participant from two randomized trials. Methods: used 2 trials comparing regorafenib to placebo; AGITG INTEGRATE IIa (n=251) for development (n=152) validation. Both enrolled metastatic or AGOC following failure of 1 more...
141 Background: Retrospective clinical studies and preclinical demonstrated that statin use during preoperative (chemo)radiation (pCRT) for rectal cancer is associated with improved survival, response, toxicity. Tumor regression following pCRT has strong prognostic significance can be assessed using MRI-based tumor grading (mrTRG), including non-operative management. SPAR was designed to prospectively evaluate the benefits of adding simvastatin (SIM) on gastrointestinal (GI) adverse events...
This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.Patients with metastatic or locally recurrent cancer oesophagus, junction stomach received docetaxel a fluoropyrimidine without for 8 cycles until progression. The primary end point was response rate (RECIST1.1). We planned enrol 100 patients, 50% expected combination therapy.A total 77 patients were enrolled. A alert from REAL3 trial...
Precision medicine aims to link molecular targets in tumours with corresponding therapies, particularly for patients rare cancers. Innovative approaches are needed translate opportunities into clinical care. The Cancer Molecular Screening and Therapeutics (MoST) program employs a screening platform identify changes of therapeutic relevance (actionable changes) master protocol multiple, parallel signal-seeking substudies, focused on therapies neglected Methods analysis: Archival pathology...
Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. We sought to determine relationships between: (a) trait hope, expectation symptom benefit from chemotherapy, and anxiety depression; (b) perceived efficacy chemotherapy; (c) unfulfilled (where expectations are not fulfilled) depression. Methods. Adult patients enrolled within stage 1 Gynecologic Cancer Intergroup Symptom Benefit Study were included. Patient. Reported outcomes collected 126...
Background The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation. Patients’ experience symptoms not well documented, and the impact treatment on has been evaluated clinical trials. We report symptom burden outcomes from stage 1 Gynecological Cancer Intergroup (GCIG) Symptom Benefit Study. Methods One hundred twenty-six receiving palliative completed 5 validated health-related quality-of-life questionnaires before starting each cycle. They also reported...
4122 Background: CAPTEM is an accepted regimen for patients (pts) with advanced pNETs. Single agent PRRT now a standard of care progressive WHO Grade 1/2 mNETs. High activity was seen PRRT/CAPTEM in single arm Phase I/II trial. This study aims to determine the combining mNETs and pNETs pts. Methods: Non-comparative randomised open label parallel group phase II trial 2:1 randomisation (experimental arm) vs. (mNETs control) (pNETS control). PRRT/CAPTEM: 7.8GBq 177 Lu Octreotate (Lutate) given...
<h3>Objective</h3> The aim of this study was to determine the optimal patient-reported outcome measure (PROM) for assessing symptom benefit in trials palliative chemotherapy women with symptomatic ovarian cancer. <h3>Methods</h3> Candidate PROMs were EORTC QLQ-C30 plus ovarian-specific QLQ-OV28, Functional Assessment Cancer Therapy-Ovarian (FACT-O), FACT Ovarian Symptom Index (FOSI), and gynecologic cancer-specific Representation Questionnaire. Predefined optimality criteria inclusion all...